Rocket Pharmaceuticals, Inc. Research and Development Expense
Rocket Pharmaceuticals, Inc. (RCKT) reported Research and Development Expense of $29.50 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-10
- Rocket Pharmaceuticals, Inc. research and development expense for the quarter ending 2026-06-30 was $29.50M, a 30.85% decline year-over-year.
- Rocket Pharmaceuticals, Inc. research and development expense for the quarter ending 2026-03-31 was $31.45M, a 12.49% decline year-over-year.
- Rocket Pharmaceuticals, Inc. research and development expense for the quarter ending 2025-12-31 was $29.35M, a 21.44% decline year-over-year.
- Rocket Pharmaceuticals, Inc. research and development expense for the quarter ending 2025-09-30 was $34.07M, a 19.49% decline year-over-year.
- Rocket Pharmaceuticals, Inc. research and development expense for fiscal 2025 was $142.01M, a 17.07% decline from fiscal 2024.
- Rocket Pharmaceuticals, Inc. research and development expense for fiscal 2024 was $171.24M, a 8.10% decline from fiscal 2023.
- Rocket Pharmaceuticals, Inc. research and development expense for fiscal 2023 was $186.34M, a 12.55% increase from fiscal 2022.
- Rocket Pharmaceuticals, Inc. research and development expense for fiscal 2022 was $165.57M, a 31.95% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 6 month as first filed | Research and Development Expense 9 month | Research and Development Expense 9 month as first filed | Research and Development Expense 12 month | Research and Development Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $29.50M 10-Q · filed 2026-08-10 | $60.95M 10-Q · filed 2026-08-10 | $90.30M derived: sum of 3 quarters · filed 2026-08-10 | $124.37M derived: sum of 4 quarters · filed 2026-08-10 | ||||
| 2026-03-31 | $31.45M 10-Q · filed 2026-05-07 | $60.80M derived: sum of 2 quarters · filed 2026-05-07 | $94.87M derived: sum of 3 quarters · filed 2026-05-07 | $137.53M derived: sum of 4 quarters · filed 2026-08-10 | ||||
| 2025-12-31 | $29.35M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $63.41M derived: sum of 2 quarters · filed 2026-02-26 | $106.07M derived: sum of 3 quarters · filed 2026-08-10 | $142.01M 10-K · filed 2026-02-26 | ||||
| 2025-09-30 | $34.07M 10-Q · filed 2025-11-06 | $76.73M derived: sum of 2 quarters · filed 2026-08-10 | $112.67M 10-Q · filed 2025-11-06 | $150.03M derived: sum of 4 quarters · filed 2026-08-10 | ||||
| 2025-06-30 | $42.66M 10-Q · filed 2026-08-10 | $78.60M 10-Q · filed 2026-08-10 | $115.96M derived: sum of 3 quarters · filed 2026-08-10 | $158.27M derived: sum of 4 quarters · filed 2026-08-10 | ||||
| 2025-03-31 | $35.94M 10-Q · filed 2026-05-07 | $73.30M derived: sum of 2 quarters · filed 2026-05-07 | $115.61M derived: sum of 3 quarters · filed 2026-05-07 | $161.96M derived: sum of 4 quarters · filed 2026-05-07 | ||||
| 2024-12-31 | $37.36M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $79.67M derived: sum of 2 quarters · filed 2026-02-26 | $126.02M derived: sum of 3 quarters · filed 2026-02-26 | $171.24M 10-K · filed 2026-02-26 | ||||
| 2024-09-30 | $42.31M 10-Q · filed 2025-11-06 | $88.66M derived: sum of 2 quarters · filed 2025-11-06 | $133.89M 10-Q · filed 2025-11-06 | $175.63M derived: sum of 4 quarters · filed 2025-11-06 | ||||
| 2024-06-30 | $46.34M 10-Q · filed 2025-08-07 | $91.57M 10-Q · filed 2025-08-07 | $133.32M derived: sum of 3 quarters · filed 2025-08-07 | $180.16M derived: sum of 4 quarters · filed 2025-08-07 | ||||
| 2024-03-31 | $45.23M 10-Q · filed 2025-05-08 | $86.97M derived: sum of 2 quarters · filed 2025-05-08 | $133.81M derived: sum of 3 quarters · filed 2025-05-08 | $185.20M derived: sum of 4 quarters · filed 2025-05-08 | ||||
| 2023-12-31 | $41.74M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $88.59M derived: sum of 2 quarters · filed 2025-02-27 | $139.97M derived: sum of 3 quarters · filed 2025-02-27 | $186.34M 10-K · filed 2025-02-27 | ||||
| 2023-09-30 | $46.84M 10-Q · filed 2024-11-07 | $98.23M derived: sum of 2 quarters · filed 2024-11-07 | $144.60M 10-Q · filed 2024-11-07 | $194.63M derived: sum of 4 quarters · filed 2025-02-27 | ||||
| 2023-06-30 | $51.38M 10-Q · filed 2024-08-06 | $97.75M 10-Q · filed 2024-08-06 | $147.79M derived: sum of 3 quarters · filed 2025-02-27 | $191.17M derived: sum of 4 quarters · filed 2025-02-27 | ||||
| 2023-03-31 | $46.37M 10-Q · filed 2024-05-07 | $96.41M derived: sum of 2 quarters · filed 2025-02-27 | $139.79M derived: sum of 3 quarters · filed 2025-02-27 | $181.15M derived: sum of 4 quarters · filed 2025-02-27 | ||||
| 2022-12-31 | $50.04M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $93.42M derived: sum of 2 quarters · filed 2025-02-27 | $134.78M derived: sum of 3 quarters · filed 2025-02-27 | $165.57M 10-K · filed 2025-02-27 | ||||
| 2022-09-30 | $43.38M 10-Q · filed 2023-11-07 | $84.74M derived: sum of 2 quarters · filed 2023-11-07 | $115.53M 10-Q · filed 2023-11-07 | $148.55M derived: sum of 4 quarters · filed 2024-02-27 | ||||
| 2022-06-30 | $41.36M 10-Q · filed 2023-08-09 | $72.15M 10-Q · filed 2023-08-09 | $105.17M derived: sum of 3 quarters · filed 2024-02-27 | $144.79M derived: sum of 4 quarters · filed 2024-02-27 | ||||
| 2022-03-31 | $30.79M 10-Q · filed 2023-05-05 | $63.81M derived: sum of 2 quarters · filed 2024-02-27 | $103.43M derived: sum of 3 quarters · filed 2024-02-27 | $127.96M derived: sum of 4 quarters · filed 2024-02-27 | ||||
| 2021-12-31 | $33.02M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $72.64M derived: sum of 2 quarters · filed 2024-02-27 | $97.17M derived: sum of 3 quarters · filed 2024-02-27 | $125.48M 10-K · filed 2024-02-27 | ||||
| 2021-09-30 | $39.62M 10-Q · filed 2022-11-04 | $39.98M 10-Q · filed 2021-11-05 | $64.15M derived: sum of 2 quarters · filed 2022-11-04 | $92.46M 10-Q · filed 2022-11-04 | $93.31M 10-Q · filed 2021-11-05 | $142.55M derived: sum of 4 quarters · filed 2023-02-28 | ||
| 2021-06-30 | $24.53M 10-Q · filed 2022-08-09 | $24.80M 10-Q · filed 2021-08-09 | $52.84M 10-Q · filed 2022-08-09 | $53.34M 10-Q · filed 2021-08-09 | $102.93M derived: sum of 3 quarters · filed 2023-02-28 | $124.59M derived: sum of 4 quarters · filed 2023-02-28 | ||
| 2021-03-31 | $28.31M 10-Q · filed 2022-05-06 | $28.54M 10-Q · filed 2021-05-10 | $78.40M derived: sum of 2 quarters · filed 2023-02-28 | $100.06M derived: sum of 3 quarters · filed 2023-02-28 | $116.79M derived: sum of 4 quarters · filed 2023-02-28 | |||
| 2020-12-31 | $50.09M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $71.75M derived: sum of 2 quarters · filed 2023-02-28 | $88.48M derived: sum of 3 quarters · filed 2023-02-28 | $105.44M 10-K · filed 2023-02-28 | $106.38M 10-K · filed 2021-03-01 | |||
| 2020-09-30 | $21.66M 10-Q · filed 2021-11-05 | $38.39M derived: sum of 2 quarters · filed 2021-11-05 | $55.34M 10-Q · filed 2021-11-05 | $69.30M derived: sum of 4 quarters · filed 2022-02-28 | ||||
| 2020-06-30 | $16.73M 10-Q · filed 2021-08-09 | $33.69M 10-Q · filed 2021-08-09 | $47.64M derived: sum of 3 quarters · filed 2022-02-28 | $62.47M derived: sum of 4 quarters · filed 2022-02-28 | ||||
| 2020-03-31 | $16.96M 10-Q · filed 2021-05-10 | $30.91M derived: sum of 2 quarters · filed 2022-02-28 | $45.74M derived: sum of 3 quarters · filed 2022-02-28 | $59.73M derived: sum of 4 quarters · filed 2022-02-28 | ||||
| 2019-12-31 | $13.95M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $28.78M derived: sum of 2 quarters · filed 2022-02-28 | $42.77M derived: sum of 3 quarters · filed 2022-02-28 | $57.91M 10-K · filed 2022-02-28 | $58.62M 10-K · filed 2020-03-06 | |||
| 2019-09-30 | $14.83M 10-Q · filed 2020-11-06 | $28.82M derived: sum of 2 quarters · filed 2020-11-06 | $43.95M 10-Q · filed 2020-11-06 | $67.64M derived: sum of 4 quarters · filed 2021-03-01 | ||||
| 2019-06-30 | $13.99M 10-Q · filed 2020-08-05 | $29.13M 10-Q · filed 2020-08-05 | $52.81M derived: sum of 3 quarters · filed 2021-03-01 | $65.87M derived: sum of 4 quarters · filed 2021-03-01 | ||||
| 2019-03-31 | $15.14M 10-Q · filed 2020-05-08 | $38.82M derived: sum of 2 quarters · filed 2021-03-01 | $51.88M derived: sum of 3 quarters · filed 2021-03-01 | $62.65M derived: sum of 4 quarters · filed 2021-03-01 | ||||
| 2018-12-31 | $23.68M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $36.74M derived: sum of 2 quarters · filed 2021-03-01 | $47.52M derived: sum of 3 quarters · filed 2021-03-01 | $53.27M 10-K · filed 2021-03-01 | ||||
| 2018-09-30 | $13.06M 10-Q · filed 2019-11-08 | $23.84M derived: sum of 2 quarters · filed 2019-11-08 | $29.59M 10-Q · filed 2019-11-08 | $34.50M derived: sum of 4 quarters · filed 2019-11-08 | ||||
| 2018-06-30 | $10.77M 10-Q · filed 2019-08-08 | $16.52M 10-Q · filed 2019-08-08 | $21.43M derived: sum of 3 quarters · filed 2019-08-08 | $26.33M derived: sum of 4 quarters · filed 2019-08-08 | ||||
| 2018-03-31 | $5.74M 10-Q · filed 2019-05-09 | $10.66M derived: sum of 2 quarters · filed 2019-05-09 | $15.55M derived: sum of 3 quarters · filed 2019-05-09 | $18.37M derived: sum of 4 quarters · filed 2019-05-09 | ||||
| 2017-12-31 | $4.92M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-08 | $9.81M derived: sum of 2 quarters · filed 2019-03-08 | $12.63M derived: sum of 3 quarters · filed 2019-03-08 | $14.92M 10-K · filed 2019-03-08 | $14.19M 10-K · filed 2018-03-07 | |||
| 2017-09-30 | $4.89M 10-Q · filed 2018-11-09 | $2.82M 10-Q · filed 2017-11-08 | $7.71M derived: sum of 2 quarters · filed 2018-11-09 | $10.00M 10-Q · filed 2018-11-09 | $13.54M 10-Q · filed 2017-11-08 | -$6.50M derived: sum of 4 quarters · filed 2019-03-08 | ||
| 2017-06-30 | $2.82M 10-Q · filed 2018-08-14 | $3.62M 10-Q · filed 2017-08-03 | $5.10M 10-Q · filed 2018-08-14 | $10.72M 10-Q · filed 2017-08-03 | -$11.39M derived: sum of 3 quarters · filed 2019-03-08 | -$2.98M derived: sum of 4 quarters · filed 2019-03-08 | ||
| 2017-03-31 | $2.29M 10-Q · filed 2018-05-11 | $7.10M 10-Q · filed 2017-05-10 | -$14.21M derived: sum of 2 quarters · filed 2019-03-08 | -$5.80M derived: sum of 3 quarters · filed 2019-03-08 | $664.00K derived: sum of 4 quarters · filed 2019-03-08 | |||
| 2016-12-31 | -$16.50M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-08 | -$8.09M derived: sum of 2 quarters · filed 2019-03-08 | -$1.62M derived: sum of 3 quarters · filed 2019-03-08 | $5.99M 10-K · filed 2019-03-08 | $31.98M 10-K · filed 2017-03-16 | |||
| 2016-09-30 | $8.41M 10-Q · filed 2017-11-08 | $14.88M derived: sum of 2 quarters · filed 2017-11-08 | $22.49M 10-Q · filed 2017-11-08 | $28.41M derived: sum of 4 quarters · filed 2017-11-08 | ||||
| 2016-06-30 | $6.46M 10-Q · filed 2017-08-03 | $14.08M 10-Q · filed 2017-08-03 | $20.00M derived: sum of 3 quarters · filed 2017-08-03 | $23.61M derived: sum of 4 quarters · filed 2017-08-03 | ||||
| 2016-03-31 | $7.62M 10-Q · filed 2017-05-10 | $13.53M derived: sum of 2 quarters · filed 2017-05-10 | $17.15M derived: sum of 3 quarters · filed 2017-05-10 | $19.10M derived: sum of 4 quarters · filed 2017-05-10 | ||||
| 2015-12-31 | $5.92M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16 | $9.53M derived: sum of 2 quarters · filed 2017-03-16 | $11.48M derived: sum of 3 quarters · filed 2017-03-16 | $12.55M 10-K · filed 2017-03-16 | ||||
| 2015-09-30 | $3.61M 10-Q · filed 2016-11-09 | $5.57M derived: sum of 2 quarters · filed 2016-11-09 | $6.63M 10-Q · filed 2016-11-09 | $7.57M derived: sum of 4 quarters · filed 2016-11-09 | ||||
| 2015-06-30 | $1.95M 10-Q · filed 2016-08-10 | $3.02M 10-Q · filed 2016-08-10 | $3.96M derived: sum of 3 quarters · filed 2016-08-10 | $5.20M derived: sum of 4 quarters · filed 2016-08-10 | ||||
| 2015-03-31 | $1.07M 10-Q · filed 2016-05-11 | $2.01M derived: sum of 2 quarters · filed 2016-05-11 | $3.25M derived: sum of 3 quarters · filed 2016-05-11 | $5.11M derived: sum of 4 quarters · filed 2016-05-11 | ||||
| 2014-12-31 | $937.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-23 | $2.18M derived: sum of 2 quarters · filed 2016-03-23 | $4.04M derived: sum of 3 quarters · filed 2016-03-23 | $5.59M 10-K · filed 2016-03-23 | ||||
| 2014-09-30 | $1.24M 10-Q · filed 2015-11-12 | $3.10M derived: sum of 2 quarters · filed 2015-11-12 | $4.66M 10-Q · filed 2015-11-12 | |||||
| 2014-06-30 | $1.86M 10-Q · filed 2015-08-07 | $3.41M 10-Q · filed 2015-08-07 | ||||||
| 2014-03-31 | $1.55M 10-Q · filed 2015-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |